The Medical Advisor

ONE-DAYMD RESOURCE HUB GLP-1 medicines, peptide therapies, emerging incretin drugs and research peptides explained in one evidence-focused library. GLP-1 drugs have moved from a diabetes niche into one of the most important areas of modern metabolic medicine. At the same time, interest has expanded into amylin analogs, GIP/GLP-1 combinations, triple agonists, growth-hormone-related peptides, regenerative peptides and other experimental compounds. This resource hub is designed to help readers distinguish between approved medicines , investigational therapies , and research-use compounds . Evidence, regulatory status and safety should always be evaluated for the specific molecule, indication, dose, route of administration and patient population. Start Here GLP-1 Medicines Next-Generation Incretins Major Peptide Medicines Research Peptides Safety Evidence Directory FAQ Edito...

TL;DR  Best weight loss:  Mounjaro Best overall balance:  Wegovy Safest long-term data:  Semaglutide class Most overlooked truth:  benefits extend beyond weight Introduction: The GLP-1 Era Has Changed Medicine Over the past decade, a new class of medications— GLP-1 receptor agonists and incretin-based therapies —has fundamentally reshaped how we treat: Obesity Type 2 diabetes Cardiovascular risk Drugs like Ozempic, Wegovy, Mounjaro, and Trulicity are no longer niche therapies. They are now: Among the most prescribed metabolic drugs globally Central to what some call the “Ozempic economy” Positioned as potential lifespan-extending interventions But with rapid adoption comes confusion—and increasingly polarized narratives: One side: “These drugs are miracle breakthroughs” The other: “We don’t fully understand them—are they risky?” The truth sits in between. This guide cuts through both hype and fear to answer one question: Which GLP-1 drug is best—and what are th...

Quick answer: Mounjaro and Zepbound contain the same active ingredient, tirzepatide . Ozempic and Wegovy contain the same active ingredient, semaglutide . The major pharmacological difference is that tirzepatide activates both the GIP and GLP-1 receptors , while semaglutide primarily activates the GLP-1 receptor . For people specifically seeking obesity treatment, direct head-to-head evidence favors tirzepatide for average weight loss. However, the "best" medication is not determined by weight loss alone. Diabetes status, cardiovascular or kidney disease, obstructive sleep apnea, side effects, contraindications, access, cost, and treatment goals all matter. Mounjaro, Ozempic, Wegovy, and Zepbound are among the most discussed medications in modern obesity and metabolic medicine. They are often grouped together as "GLP-1 drugs," but that description is incomplete. Two different molecules are involved: Semaglutide: Ozempic and Wegovy Tirzepatide: Moun...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy as “current...

By Dr. Frank Yap, MD  · One Day Media Network · Updated October 2026 · Data current to this date Quick Answer "GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition , and lower prices . As of September 29, 2026, no next-generation injectable is approved yet : retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD. Disclosure: This article is educational and is...